ArticleAntimicrobial agents and chemotherapy2008
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 154 citations in OpenAlex.
- In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.Antimicrobial agents and chemotherapy · 2012Trial
- Evaluation of Changes inOpen forum infectious diseases · 2026Article
- Whole-Genome Sequencing of Linezolid-Resistant and Linezolid-Intermediate-SusceptibilityMicroorganisms · 2025Article
- Resistance to linezolid in Staphylococcus aureus by mutation, modification, and acquisition of genes.The Journal of antibiotics · 2025Review
- Molecular Characteristics and Antimicrobial Resistance of Linezolid-ResistantInfection and drug resistance · 2025Article
- Review
- Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability.PLoS pathogens · 2024Article
- Phylogeny of Transferable Oxazolidinone Resistance Genes and Homologs.Antibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?Pathogens (Basel, Switzerland) · 2024Review
- Parallel evolution of linezolid-resistantMicrobiology spectrum · 2023Article
- Parallel Evolution of Linezolid ResistantbioRxiv : the preprint server for biology · 2023Article
- Characterization of Linezolid-Analogue L3-Resistance Mutation inMicroorganisms · 2023Article
- Lunaemycins, New Cyclic Hexapeptide Antibiotics from the Cave Moonmilk-DwellerInternational journal of molecular sciences · 2023Article
- Vancomycin Resistance inMicroorganisms · 2022Review
- Directed evolution of the rRNA methylating enzyme Cfr reveals molecular basis of antibiotic resistance.eLife · 2022Article
- Linezolid for resistant Gram-positive bacterial infections in children under 12 years: A meta-analysis.Open medicine (Warsaw, Poland) · 2022Article
- Infective endocarditis: Role of molecular techniques in early diagnosis.Saudi journal of biological sciences · 2021Review
- Genomic and Phenotypic Analysis of Linezolid-ResistantMicroorganisms · 2021Article
- Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced fromInfection and drug resistance · 2020Article
- Antibiotic Resistance and the MRSA Problem.Microbiology spectrum · 2019Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid resistance in Staphylococcus aureus is typically associated with mutations in the 23S rRNA gene. Here we show that the accumulation of a single point mutation, G2576T, in the different copies of this gene causes stepwise increases in resistance, impairment of the biological fitness, and cross-resistance to quinupristin-dalfopristin and chloramphenicol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.